Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Progress And Perspectives On Targeting Nanoparticles For Brain Drug Delivery

Authors: Huile Gao

Abstract:

Due to the ability of the blood–brain barrier (BBB) to prevent the entry of drugs into the brain, it is a challenge to treat central nervous system disorders pharmacologically. The development of nanotechnology provides potential to overcome this problem. In this review, the barriers to brain-targeted drug delivery are reviewed, including the BBB, blood–brain tumor barrier (BBTB), and nose-to-brain barrier. Delivery strategies are focused on overcoming the BBB, directly targeting diseased cells in the brain, and dual-targeted delivery. The major concerns and perspectives on constructing brain-targeted delivery systems are discussed.

Key words

Brain targeting; Nanoparticles; Dual targeting; Intranasal delivery; Blood–brain barrier

Citation: Huile Gao Progress And Perspectives On Targeting Nanoparticles For Brain Drug Delivery         doi:10.1016/j.apsb.2016.05.013

Received: 11 April 2016, Revised: 6 May 2016, Accepted: 9 May 2016, Available online: 14 June 2016

Copyright: © 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Acknowledgments

The work was funded by the National Natural Science Foundation of China (Nos. 31571016 and 81402866).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024